• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有横纹肌样特征的透明细胞肾细胞癌的分子与临床病理特征分析:一种基于整合通路的分层方法

Molecular and Clinicopathological Profiling of Clear Cell Renal Cell Carcinoma with Rhabdoid Features: An Integrative Pathway-Based Stratification Approach.

作者信息

Lu Zhichun, Zhao Qing, Xu Huihong, Katz Mark H, Wang David S, Andry Christopher D, Yang Shi

机构信息

Department of Pathology & Laboratory Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02108, USA.

Department of Pathology & Laboratory Medicine, Boston VA Health Care System, Boston, MA 02130, USA.

出版信息

Cancers (Basel). 2025 Aug 23;17(17):2744. doi: 10.3390/cancers17172744.

DOI:10.3390/cancers17172744
PMID:40940841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12427345/
Abstract

: Clear cell renal cell carcinoma with rhabdoid features (ccRCC-R) is a highly aggressive variant of renal cell carcinoma that carries a poor prognosis and limited treatment options. : To better define the clinicopathologic and molecular landscape of ccRCC-R, we conducted an integrated clinicopathologic and molecular study of 17 tumors of ccRCC-R, utilizing comprehensive histomorphologic evaluation, immunohistochemistry, and targeted next-generation sequencing (NGS). : Histologically, all tumors demonstrated classic clear cell renal cell carcinoma morphology with focal to extensive rhabdoid differentiation, characterized by eccentrically located nuclei, prominent nucleoli, abundant eosinophilic cytoplasm, and paranuclear intracytoplasmic inclusion. Architectural alterations, including solid/sheet-like, alveolar/trabecular, and pseudopapillary growth patterns, were frequently observed. Immunohistochemically, tumors commonly exhibited loss of PAX8 and Claudin4 expression, preserved cytokeratin AE1/AE3 staining, and diffuse membranous CAIX expression. Frequent loss of SMARCA2 with retained SMARCA4 supported aberrations in chromatin remodeling. Unsupervised hierarchical clustering based on pathway-specific somatic mutations identified four distinct molecular subgroups defined by recurrent alterations in (1) DNA damage repair (DDR) genes, (2) chromatin remodeling genes, (3) PI3K/AKT/mTOR signaling components, and (4) MAPK pathway genes. Clinicopathologic correlation revealed that each subgroup was associated with unique biological characteristics and suggested distinct therapeutic vulnerabilities. : Our findings underscore the molecular heterogeneity of ccRCC-R and support the utility of pathway-based stratification for guiding precision oncology approaches and biomarker-informed clinical trial design.

摘要

具有横纹肌样特征的透明细胞肾细胞癌(ccRCC-R)是肾细胞癌的一种高度侵袭性变体,预后较差且治疗选择有限。为了更好地定义ccRCC-R的临床病理和分子特征,我们对17例ccRCC-R肿瘤进行了综合临床病理和分子研究,采用了全面的组织形态学评估、免疫组织化学和靶向二代测序(NGS)。组织学上,所有肿瘤均表现出典型的透明细胞肾细胞癌形态,伴有局灶性至广泛性横纹肌样分化,其特征为核偏位、核仁突出、嗜酸性细胞质丰富以及核旁胞质内包涵体。经常观察到结构改变,包括实性/片状、腺泡状/小梁状和假乳头状生长模式。免疫组织化学方面,肿瘤通常表现为PAX8和Claudin4表达缺失,细胞角蛋白AE1/AE3染色保留,以及弥漫性膜性CAIX表达。SMARCA2频繁缺失而SMARCA4保留,支持染色质重塑异常。基于通路特异性体细胞突变的无监督层次聚类确定了四个不同的分子亚组,其定义为(1)DNA损伤修复(DDR)基因、(2)染色质重塑基因、(3)PI3K/AKT/mTOR信号成分和(4)MAPK通路基因的反复改变。临床病理相关性显示,每个亚组都与独特的生物学特征相关,并提示了不同的治疗脆弱性。我们的研究结果强调了ccRCC-R的分子异质性,并支持基于通路的分层在指导精准肿瘤学方法和生物标志物指导的临床试验设计中的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/411e30fde6ef/cancers-17-02744-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/85dd511b7419/cancers-17-02744-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/d61567ff7a81/cancers-17-02744-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/3f0314a8d472/cancers-17-02744-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/411e30fde6ef/cancers-17-02744-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/85dd511b7419/cancers-17-02744-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/d61567ff7a81/cancers-17-02744-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/3f0314a8d472/cancers-17-02744-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/991a/12427345/411e30fde6ef/cancers-17-02744-g004.jpg

相似文献

1
Molecular and Clinicopathological Profiling of Clear Cell Renal Cell Carcinoma with Rhabdoid Features: An Integrative Pathway-Based Stratification Approach.具有横纹肌样特征的透明细胞肾细胞癌的分子与临床病理特征分析:一种基于整合通路的分层方法
Cancers (Basel). 2025 Aug 23;17(17):2744. doi: 10.3390/cancers17172744.
2
Gene profiling and clinicopathological features for prognostic modeling of recurrence in non-metastatic clear-cell renal cell carcinoma.非转移性透明细胞肾细胞癌复发预后模型的基因谱分析及临床病理特征
Transl Androl Urol. 2025 Jun 30;14(6):1575-1588. doi: 10.21037/tau-2025-177. Epub 2025 Jun 26.
3
Deciphering Pseudoendocrine Sarcoma: A Clinicopathological, Molecular, and Epigenetic Study Suggesting Biological Links With Solid Pseudopapillary Neoplasm of the Pancreas.解读假性内分泌性肉瘤:一项临床病理、分子及表观遗传学研究提示其与胰腺实性假乳头状肿瘤存在生物学关联
Mod Pathol. 2025 Jun 11;38(10):100810. doi: 10.1016/j.modpat.2025.100810.
4
Comparative analysis of the roles of PBRM1 and SETD2 genes in the pathogenesis and progression of renal cell carcinoma: An analytical review.PBRM1和SETD2基因在肾细胞癌发病机制和进展中的作用比较分析:一项分析性综述
Wiad Lek. 2025;78(6):1182-1192. doi: 10.36740/WLek/205136.
5
Non-SMC condensin I complex subunit H promotes cell proliferation and inhibits cell apoptosis of clear cell renal cell carcinoma by activating the PI3K/AKT pathway.非SMC凝聚素I复合体亚基H通过激活PI3K/AKT通路促进肾透明细胞癌的细胞增殖并抑制其细胞凋亡。
Transl Androl Urol. 2025 Aug 30;14(8):2153-2170. doi: 10.21037/tau-2025-197. Epub 2025 Aug 26.
6
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
7
Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.解读线粒体自噬相关特征在透明细胞肾细胞癌临床结局和微环境异质性中的意义。
J Cancer Res Clin Oncol. 2023 Nov;149(17):16015-16030. doi: 10.1007/s00432-023-05349-y. Epub 2023 Sep 9.
8
Hemangioma-Like Clear Cell Renal Cell Carcinoma Exhibiting Aggressive Behavior and High Stage: A Case Report.表现为侵袭性行为和高分期的血管瘤样透明细胞肾细胞癌:一例报告
Int J Surg Pathol. 2025 Sep;33(6):1459-1466. doi: 10.1177/10668969241311495. Epub 2025 Feb 4.
9
PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma.PSAT1 增强了基于分期的透明细胞肾细胞癌预后评估列线图模型的疗效。
BMC Cancer. 2024 Apr 13;24(1):463. doi: 10.1186/s12885-024-12183-z.
10
Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder.SMARCA4缺陷型胆囊癌的临床病理及基因组特征
Mod Pathol. 2025 Aug 9:100868. doi: 10.1016/j.modpat.2025.100868.

本文引用的文献

1
The positive feedback loop between SP1 and MAP2K2 significantly drives resistance to VEGFR inhibitors in clear cell renal cell carcinoma.SP1和MAP2K2之间的正反馈回路显著驱动透明细胞肾细胞癌对VEGFR抑制剂的耐药性。
Int J Biol Sci. 2025 Jan 1;21(2):860-873. doi: 10.7150/ijbs.104591. eCollection 2025.
2
Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.肉瘤样和横纹肌样肾细胞癌:临床、病理和分子遗传学特征。
Am J Surg Pathol. 2024 Jul 1;48(7):e65-e88. doi: 10.1097/PAS.0000000000002233. Epub 2024 May 13.
3
A Notch signaling-related lncRNA signature for predicting prognosis and therapeutic response in clear cell renal cell carcinoma.
一个与 Notch 信号相关的 lncRNA 特征,可预测肾透明细胞癌的预后和治疗反应。
Sci Rep. 2023 Nov 30;13(1):21141. doi: 10.1038/s41598-023-48596-2.
4
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.肾细胞癌辅助治疗:2023年加拿大肾癌论坛共识声明
Can Urol Assoc J. 2023 May;17(5):E154-E163. doi: 10.5489/cuaj.8381.
5
The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.肉瘤样和横纹肌样去分化在肾细胞癌中的意义。
Cancer Treat Res Commun. 2022;33:100640. doi: 10.1016/j.ctarc.2022.100640. Epub 2022 Sep 22.
6
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.2022 年世界卫生组织泌尿系统和男性生殖器官肿瘤分类 - 第 A 部分:肾脏、阴茎和睾丸肿瘤。
Eur Urol. 2022 Nov;82(5):458-468. doi: 10.1016/j.eururo.2022.06.016. Epub 2022 Jul 16.
7
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.晚期肾癌一线联合治疗的发展态势:一项系统综述
Ther Adv Med Oncol. 2022 Jun 28;14:17588359221108685. doi: 10.1177/17588359221108685. eCollection 2022.
8
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.聚(ADP-核糖)聚合酶抑制剂作为肾细胞癌有效治疗药物的新作用
Front Oncol. 2021 Jul 9;11:681441. doi: 10.3389/fonc.2021.681441. eCollection 2021.
9
What morphology can teach us about renal cell carcinoma clonal evolution.形态学能让我们了解到关于肾细胞癌克隆进化的哪些信息。
Kidney Cancer J. 2020 Sep;18(3):68-76.
10
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.肉瘤样和横纹肌样肾细胞癌的综合分子特征。
Nat Commun. 2021 Feb 5;12(1):808. doi: 10.1038/s41467-021-21068-9.